Display options
Cite
Herrmann K, Erokwu BO, Johansen ML, et al. Dynamic Quantitative T1 Mapping in Orthotopic Brain Tumor Xenografts. Transl Oncol. 2016;9(2):147-154doi: 10.1016/j.tranon.2016.02.004.
Herrmann, K., Erokwu, B. O., Johansen, M. L., Basilion, J. P., Gulani, V., Griswold, M. A., Flask, C. A., & Brady-Kalnay, S. M. (2016). Dynamic Quantitative T1 Mapping in Orthotopic Brain Tumor Xenografts. Translational oncology, 9(2), 147-154. https://doi.org/10.1016/j.tranon.2016.02.004
Herrmann, Kelsey, et al. "Dynamic Quantitative T1 Mapping in Orthotopic Brain Tumor Xenografts." Translational oncology vol. 9,2 (2016): 147-154. doi: https://doi.org/10.1016/j.tranon.2016.02.004
Herrmann K, Erokwu BO, Johansen ML, Basilion JP, Gulani V, Griswold MA, Flask CA, Brady-Kalnay SM. Dynamic Quantitative T1 Mapping in Orthotopic Brain Tumor Xenografts. Transl Oncol. 2016 Apr;9(2):147-154. doi: 10.1016/j.tranon.2016.02.004. PMID: 27084431; PMCID: PMC4833967.
Copy Download .nbib Format: NLM
Share it on

Transl Oncol. 2016 Apr;9(2):147-154. doi: 10.1016/j.tranon.2016.02.004.

Dynamic Quantitative T1 Mapping in Orthotopic Brain Tumor Xenografts.

Translational oncology

Kelsey Herrmann, Bernadette O Erokwu, Mette L Johansen, James P Basilion, Vikas Gulani, Mark A Griswold, Chris A Flask, Susann M Brady-Kalnay

Affiliations

  1. Department of Neurosciences, School of Medicine, Case Western Reserve University, Cleveland, OH, 44106, USA. Electronic address: [email protected].
  2. Department of Radiology, School of Medicine, Case Western Reserve University, Cleveland, OH, USA. Electronic address: [email protected].
  3. Department of, Molecular Biology and Microbiology, School of Medicine, Case Western Reserve University, Cleveland, OH, 44106-4960, USA. Electronic address: [email protected].
  4. Department of Radiology, School of Medicine, Case Western Reserve University, Cleveland, OH, USA; Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA; NFCR Center for Molecular Imaging at CWRU. Electronic address: [email protected].
  5. Department of Radiology, School of Medicine, Case Western Reserve University, Cleveland, OH, USA; Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA; Department of Urology, Case Western Reserve University, Cleveland, OH, USA. Electronic address: [email protected].
  6. Department of Radiology, School of Medicine, Case Western Reserve University, Cleveland, OH, USA; Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA. Electronic address: [email protected].
  7. Department of Radiology, School of Medicine, Case Western Reserve University, Cleveland, OH, USA; Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA; Department of Pediatrics, Case Western Reserve University, Cleveland, OH, USA. Electronic address: [email protected].
  8. Department of Neurosciences, School of Medicine, Case Western Reserve University, Cleveland, OH, 44106, USA; Department of, Molecular Biology and Microbiology, School of Medicine, Case Western Reserve University, Cleveland, OH, 44106-4960, USA. Electronic address: [email protected].

PMID: 27084431 PMCID: PMC4833967 DOI: 10.1016/j.tranon.2016.02.004

Abstract

Human brain tumors such as glioblastomas are typically detected using conventional, nonquantitative magnetic resonance imaging (MRI) techniques, such as T2-weighted and contrast enhanced T1-weighted MRI. In this manuscript, we tested whether dynamic quantitative T1 mapping by MRI can localize orthotopic glioma tumors in an objective manner. Quantitative T1 mapping was performed by MRI over multiple time points using the conventional contrast agent Optimark. We compared signal differences to determine the gadolinium concentration in tissues over time. The T1 parametric maps made it easy to identify the regions of contrast enhancement and thus tumor location. Doubling the typical human dose of contrast agent resulted in a clearer demarcation of these tumors. Therefore, T1 mapping of brain tumors is gadolinium dose dependent and improves detection of tumors by MRI. The use of T1 maps provides a quantitative means to evaluate tumor detection by gadolinium-based contrast agents over time. This dynamic quantitative T1 mapping technique will also enable future quantitative evaluation of various targeted MRI contrast agents.

Copyright © 2016 Pfizer Inc. Published by Elsevier Inc. All rights reserved.

References

  1. Acta Radiol. 1997 Jan;38(1):19-24 - PubMed
  2. Radiology. 1991 Aug;180(2):485-91 - PubMed
  3. AJNR Am J Neuroradiol. 1994 Jun;15(6):1037-51 - PubMed
  4. J Magn Reson Imaging. 1992 Jan-Feb;2(1):9-18 - PubMed
  5. Genes Dev. 2007 Nov 1;21(21):2683-710 - PubMed
  6. Diagnostics (Basel). 2015;5(3):318-32 - PubMed
  7. Eur Radiol. 2000;10(7):1061-7 - PubMed
  8. J Cereb Blood Flow Metab. 2014 Aug;34(8):1354-62 - PubMed
  9. J Clin Oncol. 2010 Apr 10;28(11):1963-72 - PubMed
  10. Magn Reson Med. 2009 Aug;62(2):488-99 - PubMed
  11. Cancer Res. 2005 Aug 1;65(15):6850-7 - PubMed
  12. AJNR Am J Neuroradiol. 1994 May;15(5):983-9 - PubMed
  13. Proc Natl Acad Sci U S A. 2014 Mar 25;111(12 ):4542-7 - PubMed
  14. Magn Reson Med. 2004 May;51(5):893-9 - PubMed
  15. Cancer Res. 2011 Sep 1;71(17):5932-40 - PubMed
  16. Annu Rev Pathol. 2006;1:97-117 - PubMed
  17. EMBO J. 2007 Dec 12;26(24):4985-95 - PubMed
  18. J Neurosurg. 2011 Jul;115(1):3-8 - PubMed
  19. Br J Radiol. 2011 Dec;84 Spec No 2:S107-11 - PubMed
  20. Magn Reson Med. 1986 Dec;3(6):823-33 - PubMed
  21. J Magn Reson Imaging. 2001 Dec;14(6):795-9 - PubMed
  22. FEBS J. 2013 Nov;280(21):5350-70 - PubMed
  23. Transl Oncol. 2013 Jun 01;6(3):329-37 - PubMed
  24. N Engl J Med. 2005 Mar 10;352(10 ):987-96 - PubMed
  25. J Natl Cancer Inst. 2011 May 4;103(9):714-36 - PubMed

Publication Types

Grant support